Less Ads, More Data, More Tools Register for FREE

LONDON BROKER RATINGS: Exane BNP and HSBC cut BP; JPM likes Barclays

Thu, 12th Feb 2026 09:46

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

----------

FTSE 100

----------

Exane BNP cuts BP to 'neutral' (outperform) - price target 465 pence

----------

HSBC cuts BP to 'reduce' - price target 430 pence

----------

UBS cuts BP price target to 455 (465) pence - 'neutral'

----------

Goldman Sachs raises AstraZeneca price target to 16,496 (16,389) pence - 'buy'

----------

LBBW raises AstraZeneca price target to 16,000 (14,000) pence - 'buy'

----------

JPMorgan raises Barclays price target to 590 (570) pence - 'overweight'

----------

JPMorgan cuts NatWest price target to 730 (750) pence - 'overweight'

----------

RBC cuts Barratt Redrow price target to 425 (450) pence - 'sector perform'

----------

FTSE 250

----------

Panmure Liberum raises Ashmore Group price target to 350 (240) pence - 'buy'

----------

JPMorgan reinitiates Unite Group with 'overweight' - price target 725 pence

----------

Jefferies cuts HgCapital Trust to 'underperform' (hold)

----------

SMALL CAP

----------

Goldman Sachs cuts Flutter Entertainment price target to 19,700 (22,300) pence - 'buy'

----------

JPMorgan raises Smurfit Westrock target to 5,000 (4,300) pence - 'overweight'

----------

RBC cuts MJ Gleeson price target to 375 (400) pence - 'underperform'

----------

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

MJGleeson Smurfit West Flutter Entertainment HgCapital Trust plc Unite Ashmore Group Barratt Redrow Natwest Barclays Astrazeneca BP

Shares in this article

Related News

LONDON MARKET CLOSE: Miners lift FTSE 100 while oil price heads lower
17 hours ago

LONDON MARKET CLOSE: Miners lift FTSE 100 while oil price heads lower

(Alliance News) - The FTSE 100 made steady progress on Tuesday, with events in the Middle East continuing to largely dictate the market mood.

Market News Elementis + 12 more shares
AstraZeneca breast cancer drug camizestrant shows "sustained" benefit
20 hours ago

AstraZeneca breast cancer drug camizestrant shows "sustained" benefit

(Alliance News) - AstraZeneca PLC on Tuesday reported encouraging test results for its breast cancer treatment camizestrant.

BSF Enterprise shares jump on paper in praise of "T-rex leather"
22 hours ago

BSF Enterprise shares jump on paper in praise of "T-rex leather"

(Alliance News) - BSF Enterprise on Tuesday saw its shares rise after the publication of a paper on one of its subsidiaries' synthetic leather product...